BIOMAT Database Logo BIOMAT Database Logo

Population pharmacokinetics and model-based dosing optimization of teicoplanin in elderly critically ill patients with pneumonia. 2023

Sung Wook Kang, and Hyeong Geun Jo, and Donghyun Kim, and Kyeoul Jeong, and Jaeok Lee, and Hwa Jeong Lee, and Seungwon Yang, and Sohyun Park, and Sandy Jeong Rhie, and Eun Kyoung Chung
Department of Pulmonary and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of Korea.

To evaluate the population pharmacokinetics and pharmacodynamics of teicoplanin in elderly critically ill patients with pneumonia for optimal dosages. Fifteen critically ill patients (9 men) ≥ 60 years received teicoplanin 6 mg/kg for three doses followed by standard maintenance doses (6 mg/kg q24h) with renal dosing adjustment. Serial plasma samples from all patients were analyzed simultaneously by population pharmacokinetic modeling using NONMEM. Probability of target attainment (PTA) was calculated through Monte Carlo simulations for various dosing regimens to achieve adequate systemic exposures. The median (interquartile range, IQR) age, body mass index, and creatinine clearance (CrCl) was 75 (64-78) years, 22.5 (20.8-25.4) kg/m2, and 64 (47-106) mL/min, respectively. The median (IQR) peak and trough concentration was 46.5 (42.7-51.0) and 8.7 (7.2-9.5) mg/L. The population pharmacokinetic model showed slower clearance (CL) and larger peripheral volume of distribution (V2) in patients with reduced CrCl: CL (L/h) = 0.629 × (CrCl/64)0.656, V2 (L) = 55.7 × (CrCl/64)-0.665. Model-based simulations showed PTAs ≥85% only for higher-dose regimens (12 mg/kg) up to an MIC of 0.5 mg/L. Standard teicoplanin dosages for pneumonia may provide inadequate systemic exposures in elderly critically ill patients. High-dose regimens should be considered as empiric therapy or for less susceptible pathogens.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009010 Monte Carlo Method In statistics, a technique for numerically approximating the solution of a mathematical problem by studying the distribution of some random variable, often generated by a computer. The name alludes to the randomness characteristic of the games of chance played at the gambling casinos in Monte Carlo. (From Random House Unabridged Dictionary, 2d ed, 1993) Method, Monte Carlo
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D015992 Body Mass Index An indicator of body density as determined by the relationship of BODY WEIGHT to BODY HEIGHT. BMI Quetelet Index,Quetelet's Index,Index, Body Mass,Index, Quetelet,Quetelets Index
D016638 Critical Illness A disease or state in which death is possible or imminent. Critically Ill,Critical Illnesses,Illness, Critical,Illnesses, Critical
D017334 Teicoplanin Lipoglycopeptide antibiotic from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety. Teichomycin,Targocid,Teichomycin A2

Related Publications

Sung Wook Kang, and Hyeong Geun Jo, and Donghyun Kim, and Kyeoul Jeong, and Jaeok Lee, and Hwa Jeong Lee, and Seungwon Yang, and Sohyun Park, and Sandy Jeong Rhie, and Eun Kyoung Chung
Population Pharmacokinetics and Model-Based Dosing Optimization of Teicoplanin in Pediatric Patients.
January 2020, Frontiers in pharmacology,
Sung Wook Kang, and Hyeong Geun Jo, and Donghyun Kim, and Kyeoul Jeong, and Jaeok Lee, and Hwa Jeong Lee, and Seungwon Yang, and Sohyun Park, and Sandy Jeong Rhie, and Eun Kyoung Chung
Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
January 2023, Frontiers in pharmacology,
Sung Wook Kang, and Hyeong Geun Jo, and Donghyun Kim, and Kyeoul Jeong, and Jaeok Lee, and Hwa Jeong Lee, and Seungwon Yang, and Sohyun Park, and Sandy Jeong Rhie, and Eun Kyoung Chung
Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type.
January 2023, Drug design, development and therapy,
Sung Wook Kang, and Hyeong Geun Jo, and Donghyun Kim, and Kyeoul Jeong, and Jaeok Lee, and Hwa Jeong Lee, and Seungwon Yang, and Sohyun Park, and Sandy Jeong Rhie, and Eun Kyoung Chung
Teicoplanin pharmacokinetics in critically ill paediatric patients.
September 1999, The Journal of antimicrobial chemotherapy,
Sung Wook Kang, and Hyeong Geun Jo, and Donghyun Kim, and Kyeoul Jeong, and Jaeok Lee, and Hwa Jeong Lee, and Seungwon Yang, and Sohyun Park, and Sandy Jeong Rhie, and Eun Kyoung Chung
Population pharmacokinetics and dosing optimization of unbound teicoplanin in Chinese adult patients.
January 2022, Frontiers in pharmacology,
Sung Wook Kang, and Hyeong Geun Jo, and Donghyun Kim, and Kyeoul Jeong, and Jaeok Lee, and Hwa Jeong Lee, and Seungwon Yang, and Sohyun Park, and Sandy Jeong Rhie, and Eun Kyoung Chung
Population Pharmacokinetics of Unbound and Total Teicoplanin in Critically Ill Pediatric Patients.
March 2021, Clinical pharmacokinetics,
Sung Wook Kang, and Hyeong Geun Jo, and Donghyun Kim, and Kyeoul Jeong, and Jaeok Lee, and Hwa Jeong Lee, and Seungwon Yang, and Sohyun Park, and Sandy Jeong Rhie, and Eun Kyoung Chung
Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients.
March 2023, European journal of hospital pharmacy : science and practice,
Sung Wook Kang, and Hyeong Geun Jo, and Donghyun Kim, and Kyeoul Jeong, and Jaeok Lee, and Hwa Jeong Lee, and Seungwon Yang, and Sohyun Park, and Sandy Jeong Rhie, and Eun Kyoung Chung
Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
January 2022, Drug design, development and therapy,
Sung Wook Kang, and Hyeong Geun Jo, and Donghyun Kim, and Kyeoul Jeong, and Jaeok Lee, and Hwa Jeong Lee, and Seungwon Yang, and Sohyun Park, and Sandy Jeong Rhie, and Eun Kyoung Chung
Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function.
October 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Sung Wook Kang, and Hyeong Geun Jo, and Donghyun Kim, and Kyeoul Jeong, and Jaeok Lee, and Hwa Jeong Lee, and Seungwon Yang, and Sohyun Park, and Sandy Jeong Rhie, and Eun Kyoung Chung
Population-Based Pharmacokinetics and Dose Optimization of Imipenem in Vietnamese Critically-Ill Patients.
January 2022, Infection and drug resistance,
Copied contents to your clipboard!